Reta is a 39 amino acid peptide that is resistant to cleavage by DPP4, an enzyme that cleaves GLP-1 and GIP. The peptide is constructed from the GIP peptide backbone to achieve triple agonist activity against GCGR (glucagon receptors), GIPR and GLP-1R. The retatrutide peptide base sequence contains three non-coding amino acid residues. Aib2 provides stability against DPP4 cleavage, just like in semaglutide and tyrzepatide molecules.
Reta is a synthetic peptide studied as a triple agonist of GLP-1, GIP and glucagon receptors. In the research context, Retatrutide is considered in connection with metabolic regulation, appetite control, glycemia and body weight.
General information
| Features | Values |
|---|---|
| The peptide sequence | Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-αMeLeu-Leu-Asp-Lys-Lys(AEEA-γGlu-C20 diacid)-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2. |
| The molecular formula | C221H342N46O68 |
| Molecular weight | 4731 g/mol |
| CAS Number | 2381089-83-2 |
| PubChem CID | 171390338 |
| Synonyms | Retatrutide, LY3437943 |
Lyophilized peptides
All peptides undergo lyophilization, a process that is necessary to extend their shelf life, as well as preserve the purity and integrity of the peptides during storage and transportation. Product Usage: This product is intended solely for research purposes. All product information provided on this website is intended for educational purposes.
Product Usage
This product is intended solely for research purposes. All product information provided on this website is intended for educational purposes.
The purity of peptides is more than 99%
Confirmed by certified laboratories. The analysis certificates are available before purchase.
GMR Production Standards
Manufactured in enterprises in accordance with good manufacturing practices. Complete documentation on tracking the origin of the product.
Execution of orders at the highest level
Sending orders the next day at checkout before 12:00 Moscow time. Free standard shipping across the country for orders starting from 15,000₽ (or equivalent).
Without fillers and additives
Only pure active connections. The composition is confirmed by experts for reliable in vitro studies.
Retatrutide is a new generation synthetic incretin peptide that simultaneously activates three receptors: GIP, GLP-1 and the glucagon receptor. It is this triple activity that distinguishes it from earlier molecules and makes it one of the most notable candidates for research on body weight control, glycemia, fat metabolism, and broader cardiometabolic regulation. In published papers, retatrutide is described as a once-weekly triple agonist, and in Lilly's clinical programs it is already in a late stage of development on obesity and related metabolic conditions. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial | New England Journal of Medicine
Body weight control
The main research area of retatrutide is associated with a pronounced effect on body weight and appetite. In phase 2, in obese or overweight adults without diabetes, the average decrease in body weight by week 48 reached 22.8% at a dose of 8 mg and 24.2% at 12 mg, and in some participants the decrease approached 25% or more, which made retatrutide one of the most discussed molecules in obesity research. It was these data that generated a high interest in its further study as a triple agonist for deep metabolic correction. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial | New England Journal of Medicine
Glucose regulation and type 2 diabetes mellitus
Retatrutide is also being actively studied in the context of carbohydrate metabolism. In phase 2, in patients with type 2 diabetes mellitus, it reduced HbA1c and body weight compared with placebo and dulaglutide 1.5 mg, and was accompanied by favorable dynamics of a number of cardiometabolic parameters, including triglycerides, blood pressure and non-HDL cholesterol. As of March 2026, Lilly has already reported positive late-stage results for type 2 diabetes, which further increases interest in the molecule as a multifunctional metabolic peptide. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA - ScienceDirect
Liver fat and metabolic dysfunction
Separately, retatrutide is being investigated in models of MASLD and ectopic fat accumulation. The publication Nature Medicine shows that in obese and high-liver fat participants, the drug caused a very pronounced decrease in liver fat as early as the 24th week, and in a significant part of the participants, liver parameters returned to normal. This makes retatrutide particularly interesting not only for weight control, but also for studying the relationship between obesity, insulin resistance, and fatty liver disease. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial - PubMed
Body composition
Another important area is related to the quality of weight loss. According to the 2025 study, retatrutide in people with type 2 diabetes resulted in a more pronounced reduction in total fat mass compared to placebo and dulaglutide, while the ratio of fat-free weight loss to total weight loss was comparable to other modern anti-obesity approaches. This is important for the research assessment of body recomposition, because the interest in retatrutide is not just related to the number on the scale, but to the depth of the change in the fat component. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial - PubMed
Cardiometabolic and long-term studies
Retatrutide is also of interest as a molecule for studying broader obesity-related outcomes. As of 2025-2026, Lilly is conducting several major phase 3 studies, including programs for obesity with cardiovascular diseases, chronic kidney disease, to maintain weight loss, and even a separate outcomes study on cardiovascular and renal outcomes. This shows that retatrutide is considered not only as a means for weight loss, but also as a potential tool for long-term cardiometabolic risk modification. b7c7e82b-e667-42ba-827c-1faecba3e4c8
Links
1. Jastreboff A. M. et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine, 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
2. Rosenstock J. et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for type 2 diabetes and obesity. The Lancet, 2023. https://www.sciencedirect.com/science/article/abs/pii/S014067362301053X
3. Sanyal A. J. et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease. Nature Medicine, 2024. https://www.nature.com/articles/s41591-024-03018-2
4. Coskun T. et al. Effects of retatrutide on body composition in people with type 2 diabetes. The Lancet Diabetes & Endocrinology, 2025. https://www.thelancet.com/journals/landia/article/PIIS2213-8587%2825%2900092-0/abstract?utm_source=chatgpt.com
5. Eli Lilly Q2 2025 earnings materials, Select Trials – Retatrutide section. https://investor.lilly.com/static-files/b7c7e82b-e667-42ba-827c-1faecba3e4c8?utm_source=chatgpt.com
6. ClinicalTrials.gov . (http://clinicaltrials.gov /) TRIUMPH-3 and TRIUMPH-OUTCOMES. https://clinicaltrials.gov/study/NCT05882045